Evaluation of the Safety and Efficacy of Pancrecarb® MS-16 in Cystic Fibrosis - Related Studies

Evaluation of the Safety and Efficacy of Pancrecarb® MS-16 in Cystic Fibrosis

This study has been completed.

Study NCT00432861. Last updated on August 29, 2008. Information provided by Digestive Care, Inc.

Find Related Studies by Searching for the Conditions, Interventions, and Sponsors found in this study:


1	Conditions listed in this trial
		Cystic Fibrosis
		Pancreatic Insufficiency

2	Additional conditions recognized in this trial
		Exocrine Pancreatic Insufficiency
		Fibrosis

3	More general conditions related to this trial
		Digestive System Diseases
		Genetic Diseases, Inborn
		Infant, Newborn, Diseases
		Lung Diseases
		Pancreatic Diseases
		Pathologic Processes
		Respiratory Tract Diseases

4	Interventions listed in this trial
		PANCRECARB® (pancrelipase)
		Placebo

5	Additional drug interventions recognized in this trial
		Pancrelipase

6	More general drug interventions related to this trial
		Gastrointestinal Agents
		Pharmacologic Actions
		Therapeutic Uses

7	Sponsors listed in this trial
		Digestive Care, Inc.